Drug Approval | April 14, 2026
FDA fast-tracks Daiichi Sankyo & Merck lung cancer drug review
The FDA is also reviewing the application under its Real-Time Oncology Review (RTOR) program and Project Orbis
The FDA is also reviewing the application under its Real-Time Oncology Review (RTOR) program and Project Orbis
Benefits were consistent across all key subgroups, including patients previously treated with covalent BTK inhibitors
A brand from Opella will be part of the official NASA astronaut formulary
With the expansion, the hospital’s total bed capacity will rise from 380 to 539 beds
Highlights Mirvetuximab-based regimen promise
The centre offers a full spectrum of FDA-approved services, including physiotherapy, occupational therapy, speech and language therapy, and aqua therapy
The conference focuses on the latest advances in cancer diagnosis, treatment, and patient-centric care
At the centre of this shift is Eli Lilly and Company, whose latest investments in China and Japan are helping redefine the next phase of GLP-1 supply strategy
The two-day conference and exhibition features discussions on policy frameworks, AI-led drug discovery, next-generation technologies, and global competitiveness
Hyderabad-based peptide specialist strengthens complex generics credentials as Apotex prepares for U.S. commercialization of semaglutide injection
Subscribe To Our Newsletter & Stay Updated
